TrialCancer medicine2022

Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial.

Sriram Balasubramanian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.